(Q36391426)

13 August 2017

1 reference

title

Advances in radioimmunotherapy in the age of molecular engineering and pretargeting (English)

1 reference

13 August 2017

Robert M Sharkey

1

1 reference

13 August 2017

David M Goldenberg

series ordinal

2

1 reference

13 August 2017

publication date

1 February 2006

1 reference

13 August 2017

1 reference

13 August 2017

volume

24

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

82-97

1 reference

Radioimmunotherapy of non-Hodgkin's lymphoma: a critical appraisal

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

The radioisotope contributes significantly to the activity of radioimmunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Radiolabeling of monoclonal antibodies and fragments with technetium and rhenium

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Nonuniform absorbed dose distribution in the kidney: the influence of organ architecture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: an autoradiographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Radioimmunotherapy of small-volume disease of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Application of extracorporeal immunoadsorption to reduce circulating blood radioactivity after intraperitoneal administration of indium-111-HMFG1-biotin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Development of humanized antibodies as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

SDR grafting--a new approach to antibody humanization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

A novel monoclonal antibody design for radioimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Antibody engineering: advances from the use of Escherichia coli expression systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Engineering antibodies for clinical applications in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Radioimmunotherapy with engineered antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Antibody engineering for therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Naturally occurring antibodies devoid of light chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Efficient cancer therapy with a nanobody-based conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Isolation of the new antigen receptor from wobbegong sharks, and use as a scaffold for the display of protein loop libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Evidence of antisense tumor targeting in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Monoclonal antibodies as reversible equilibrium carriers of radiopharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Imaging of colorectal carcinoma with technetium-99m radiolabeled Fab' fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Experimental pretargeting studies of cancer with a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct and a (99m)Tc-/(188)Re-labeled peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Intraperitoneal radio-localization of tumors pre-targeted by biotinylated monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein for pretargeted cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Comparison of IgG and F(ab')2 fragments of bispecific anti-RCCxanti-DTIn-1 antibody for pretargeting purposes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

Antibodies against metal chelates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500449553

10.1080/07357900500449553

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference